A Phase II Trial Evaluating the Safety and the Efficacy of High-Dose Imatinib in Relapsed/Refractory c-Kit Positive and BCR-Abl Negative AML Patients
Daily dosing of imatinib 600 mg/day is planned for one month or until progression of
disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the
event of response failure. Novartis provided supplies of imatinib for all patients included
in the study.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
France: French Data Protection Authority
BRD 03/3-B
NCT00707408
February 2004
January 2009
Name | Location |
---|